These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 12611618)

  • 1. Pharyngeal pituitary non-functioning adenoma with normal intra-sellar gland: massive tumor shrinkage on octreotide therapy.
    Pugnale N; Waridel F; Bouzourène H; Boubaker A; Pugnale M; Gaillard RC; Gomez F
    Eur J Endocrinol; 2003 Mar; 148(3):357-64. PubMed ID: 12611618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology.
    Plöckinger U; Bäder M; Hopfenmüller W; Saeger W; Quabbe HJ
    Eur J Endocrinol; 1997 Apr; 136(4):369-76. PubMed ID: 9150695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
    Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
    Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas.
    Colao A; Lastoria S; Ferone D; Varrella P; Marzullo P; Pivonello R; Cerbone G; Acampa W; Salvatore M; Lombardi G
    J Endocrinol Invest; 1999 Mar; 22(3):176-83. PubMed ID: 10219884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide.
    Broson-Chazot F; Houzard C; Ajzenberg C; Nocaudie M; Duet M; Mundler O; Marchandise X; Epelbaum J; Gomez De Alzaga M; Schäfer J; Meyerhof W; Sassolas G; Warnet A
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):589-98. PubMed ID: 9425399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Gonadotropi adenoma linking labeled somatostatin analogs. Lack of relationship with therapeutic effect].
    Evrard A; Vantyghem MC; Huglo D; Hober C; Marchandise X; Mazzuca M; Lefebvre J
    Ann Endocrinol (Paris); 1996; 57(3):209-14. PubMed ID: 8949416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR.
    Lundin P; Edén Engström B; Karlsson FA; Burman P
    AJNR Am J Neuroradiol; 1997 Apr; 18(4):765-72. PubMed ID: 9127047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyrotropin secreting pituitary adenoma effectively treated with octreotide.
    Fukuda T; Yokoyama N; Tamai M; Imaizumi M; Kimura H; Tominaga T; Ashizawa K; Kiriyama T; Yoshimine H; Ohishi K; Eguchi K
    Intern Med; 1998 Dec; 37(12):1027-30. PubMed ID: 9932634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin receptor imaging in non-functioning pituitary adenomas: value of an uptake index.
    Duet M; Mundler O; Ajzenberg C; Berolatti B; Chedin P; Duranteau L; Warnet A
    Eur J Nucl Med; 1994 Jul; 21(7):647-50. PubMed ID: 7957351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term preoperative management of thyrotropin-secreting pituitary adenoma with octreotide.
    Iglesias P; Díez JJ
    J Endocrinol Invest; 1998 Dec; 21(11):775-8. PubMed ID: 9972679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.
    Ferone D; Lastoria S; Colao A; Varrella P; Cerbone G; Acampa W; Merola B; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 1998 Jan; 83(1):248-52. PubMed ID: 9435450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful management of octreotide-insensitive thyrotropin-secreting pituitary adenoma with bromocriptine and surgery: A case report and literature review.
    Yang C; Wu H; Wang J; Hu M; Xing X; Bao X; Wang R
    Medicine (Baltimore); 2017 Sep; 96(36):e8017. PubMed ID: 28885368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrasellar paraganglioma: a case report and review of the literature.
    Boari N; Losa M; Mortini P; Snider S; Terreni MR; Giovanelli M
    Acta Neurochir (Wien); 2006 Dec; 148(12):1311-4; discussion 1314. PubMed ID: 17039304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance imaging after transsphenoidal surgery of clinically non-functional pituitary macroadenomas and its impact on detecting residual adenoma.
    Kremer P; Forsting M; Ranaei G; Wüster C; Hamer J; Sartor K; Kunze S
    Acta Neurochir (Wien); 2002 May; 144(5):433-43. PubMed ID: 12111499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients.
    Famini P; Maya MM; Melmed S
    J Clin Endocrinol Metab; 2011 Jun; 96(6):1633-41. PubMed ID: 21470998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
    Plöckinger U; Quabbe HJ
    Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ectopic pituitary adenoma of the TSH-secreting sphenoidal sinus with excellent response to somatostatin analogs. Theory of the embryogenesis and literature review from a clinical case.
    Ortiz E; Peldoza M; Monnier E; Gejman R; Henriquez M; Barra MI; Gayoso R; Sapunar J; Villaseca M; Guzmán P
    Steroids; 2020 Feb; 154():108535. PubMed ID: 31704334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
    Amato G; Mazziotti G; Rotondi M; Iorio S; Doga M; Sorvillo F; Manganella G; Di Salle F; Giustina A; Carella C
    Clin Endocrinol (Oxf); 2002 Jan; 56(1):65-71. PubMed ID: 11849248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin receptor scintigraphy in pituitary adenomas: a somatostatin receptor density index can predict hormonal and tumoral efficacy of octreotide in vivo.
    Duet M; Ajzenberg C; Benelhadj S; Lajeunie E; Lormeau B; Guillausseau PJ; Rohmer V; Vilain D; Mundler O; Warnet A
    J Nucl Med; 1999 Aug; 40(8):1252-6. PubMed ID: 10450674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.